

IMMUNOVANT, INC.
320 West 37th Street
New York, NY 10018

April 8, 2020

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

Re: Immunovant, Inc.
Registration Statement on Form S-1
File No. 333-235975

Acceleration Request
Requested Date:
Requested Time:

April 9, 2020
5:30 p.m., Eastern Daylight Time

Ladies and Gentlemen:

The undersigned registrant hereby requests that the staff of the U.S. Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-235975) to become effective on April 9, 2020, at 5:30 p.m., Eastern Daylight Time, or as soon as practicable thereafter.

Very truly yours,

Immunovant, Inc.

By: /s/ Peter Salzmann, M.D.

Name: Peter Salzmann, M.D.

Title: Chief Executive Officer

cc: Pamela Yanchik Connealy, *Immunovant, Inc.*
W. Bradford Middlekauff, *Immunovant, Inc.*
Frank F. Rahmani, *Cooley LLP*
John T. McKenna, *Cooley LLP*
Alison A. Haggerty, *Cooley LLP*